Clinical Trial News and Research

RSS

Patient enrollment and trial duration heavily impact the total cost of Phase 1 oncology trial

Both the number of patients and trial duration heavily impact a Phase 1 oncology trial's total cost. The underlying force driving most costs is patient enrollment. As the time to reach full enrollment increases, the trial lasts longer and the cost of maintaining and staffing clinical sites rises.

19 Jun 2013

Signaling pathway correlates with EGFR status and poor survival in breast cancer patients

Researchers have discovered and mapped the signaling network between two previously unconnected proteins, exposing a link that, if broken, could cut off cancer cell growth at its starting point.

19 Jun 2013

OHSU analysis finds previous studies have overstated effectiveness of bone growth product used in spinal surgeries

An analysis by the Evidence-based Practice Center at Oregon Health & Science University has found that previously published clinical trial studies about a controversial bone growth product used in spinal surgeries overstated the product's effectiveness.

19 Jun 2013

UHCMC physicians design new procedure to clear blocked carotid arteries, prevent stroke

Physicians at University Hospitals Case Medical Center enrolled their first patients in the ROADSTER Study, a global, multicenter clinical trial evaluating a novel, less-invasive procedure to help clear blockages in carotid arteries and prevent strokes.

19 Jun 2013

OncoSec Medical completes enrollment in ImmunoPulse trial for metastatic melanoma patients

OncoSec Medical Inc., a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced the completion of patient enrollment in a Phase II clinical trial of ImmunoPulse for metastatic melanoma patients.

18 Jun 2013

Estrogen replacement therapy reduces anxiety symptoms in girls with anorexia nervosa

Estrogen replacement therapy is associated with a significant decrease in anxiety symptoms among girls with anorexia nervosa, a new clinical trial finds. The results will be presented today at The Endocrine Society's Annual Meeting in San Francisco.

18 Jun 2013

Study: Whole body vibration therapy raises bone strength among adolescents with cerebral palsy

A treatment known as whole body vibration therapy significantly increases bone strength among adolescents with cerebral palsy, a new clinical trial from New Zealand shows. The results were presented Saturday at The Endocrine Society's 95th Annual Meeting in San Francisco.

18 Jun 2013

TWi Biotechnology completes patient enrollment in phase II trial of AC-201 for Gout Flare Prophylaxis

TWi Biotechnology, Inc. announced that it has completed the patient enrollment in a phase II trial of AC-201 for Gout Flare Prophylaxis during urate-lowering therapy. This randomized, double-blind, placebo-controlled Phase II study is conducted in 8 major medical centers in Taiwan.

18 Jun 2013

Researchers to study benefits, side effects of four widely used therapies in adults with type 2 diabetes

UT Southwestern Medical Center researchers are seeking 150 adults with type 2 diabetes to take part in the local arm of a major national clinical trial that will compare benefits and side effects of four widely used therapies to lower blood-sugar levels.

18 Jun 2013

Men with low-risk prostate cancers can choose watchful waiting for better quality of life, study says

Many men with low-risk, localized prostate cancers can safely choose active surveillance or "watchful waiting" instead of undergoing immediate treatment and have better quality of life while reducing health care costs, according to a study by researchers at Dana-Farber Cancer Institute and Massachusetts General Hospital.

18 Jun 2013

Athera receives support from FP7 for development of fully human antibody PC-mAb

Athera Biotechnologies AB today announced that future development costs of its fully human antibody PC-mAb up until proof-of-concept will be co-funded by the European Union's Seventh Framework Programme for Research (FP7) through a collaborative research grant. Karolinska Development AB owns 65% of Athera Biotechnologies AB.

17 Jun 2013

FDA approves MENTOR MemoryShape Breast Implants

Mentor Worldwide LLC, the U.S. market leader in breast aesthetics, today announced the U.S. Food and Drug Administration has approved MENTOR MemoryShape Breast Implants, providing new options for women looking for a more natural shape and youthful feel from breast enhancement or reconstruction surgery.

15 Jun 2013

Irene Pollin gifts $10 million to the Ciccarone Center for Prevention of Heart Disease

Irene Pollin, a passionate health advocate and founder of a national organization devoted to heart disease prevention in women, has made a $10 million gift to the Ciccarone Center for the Prevention of Heart Disease.

15 Jun 2013

Elcelyx Therapeutics' posters related to NewMet to be presented at ADA's 73rd Scientific Sessions

Elcelyx Therapeutics today announced that the company and principal investigator Ralph A. DeFronzo, M.D. will present posters related to NewMet, a delayed-release formulation of generic metformin, at the 73rd Scientific Sessions of the American Diabetes Association in Chicago, IL.

15 Jun 2013

Study demonstrates efficacy of canakinumab at tapering corticosteroid use in patients with SJIA

Study findings first presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrate the efficacy of canakinumab at tapering corticosteroid (CS) use in patients with SJIA.

14 Jun 2013

Penn Medicine researchers identify key molecular player in recurrent breast cancer

According to the American Cancer Society, nearly 40,000 women in the United States will succumb to breast cancer this year. Most of these women will die not from the primary tumor but rather tumor recurrence - the reappearance of the disease following treatment.

14 Jun 2013

NACC recommendations address established pain therapies and preview potential future advances

Recommendations of the Neuromodulation Appropriateness Consensus Committee (NACC), announced at the 11th World Congress of the International Neuromodulation Society (INS), address established therapies and preview emerging and potential future advances.

13 Jun 2013

PRISM Pharma announces closing of $15 million Series C financing

PRISM Pharma Co., Ltd., a drug discovery company focused on developing small molecule technologies that modulate protein-protein interactions, today announced the close of an approximately $15 million (approximately ¥1.4 billion) Series C financing.

13 Jun 2013

Omeros gets regulatory clearance to begin Phase 1 clinical trial of OMS721

Omeros Corporation today announced that it has obtained regulatory clearance to start the Phase 1 clinical trial evaluating OMS721, the Company's lead human monoclonal antibody from its mannan-binding lectin-associated serine protease-2 (MASP-2) program.

13 Jun 2013

Investigational all-oral interferon-free combination from Boehringer Ingelheim achieves 95% viral cure rates in genotype-1b hepatitis C patients

New data from Boehringer Ingelheim’s interferon-free SOUND-C3 study were presented during the APASL Liver Week in Singapore. The Phase IIb study investigated the efficacy and safety of faldaprevir+ and deleobuvir+ (BI 207127) plus ribavirin in treatment-naïve patients with genotype-1b (GT-1b) hepatitis C virus (HCV),1 one of the most common types of HCV globally.2

13 Jun 2013

Clinical Trial News and Research

Patient enrollment and trial duration heavily impact the total cost of Phase 1 oncology trial

Signaling pathway correlates with EGFR status and poor survival in breast cancer patients

OHSU analysis finds previous studies have overstated effectiveness of bone growth product used in spinal surgeries

UHCMC physicians design new procedure to clear blocked carotid arteries, prevent stroke

OncoSec Medical completes enrollment in ImmunoPulse trial for metastatic melanoma patients

Estrogen replacement therapy reduces anxiety symptoms in girls with anorexia nervosa

Study: Whole body vibration therapy raises bone strength among adolescents with cerebral palsy

TWi Biotechnology completes patient enrollment in phase II trial of AC-201 for Gout Flare Prophylaxis

Researchers to study benefits, side effects of four widely used therapies in adults with type 2 diabetes

Men with low-risk prostate cancers can choose watchful waiting for better quality of life, study says

Athera receives support from FP7 for development of fully human antibody PC-mAb

FDA approves MENTOR MemoryShape Breast Implants

Irene Pollin gifts $10 million to the Ciccarone Center for Prevention of Heart Disease

Elcelyx Therapeutics' posters related to NewMet to be presented at ADA's 73rd Scientific Sessions

Study demonstrates efficacy of canakinumab at tapering corticosteroid use in patients with SJIA

Penn Medicine researchers identify key molecular player in recurrent breast cancer

NACC recommendations address established pain therapies and preview potential future advances

PRISM Pharma announces closing of $15 million Series C financing

Omeros gets regulatory clearance to begin Phase 1 clinical trial of OMS721

Investigational all-oral interferon-free combination from Boehringer Ingelheim achieves 95% viral cure rates in genotype-1b hepatitis C patients

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer